Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseNEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.

A team of Ohio State researchers engineered a new antibody that could revolutionize influenza prevention through a nasal ...

This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients ...

Ten patients with na-SPMS, who continued to progress despite B-cell therapy, were treated with nasal foralumab for a minimum of six months. No serious or severe treatment-related adverse events ...

This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients ...

This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients ...

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded ...

The study examines the monoclonal antibody Foralumab, made by Tiziana ... “We envision giving a nasal spray right there on the sidelines,” said Weiner. “It isn’t something we can do yet, but we see ...

When delivered intravenously, foralumab kills T cells, but when introduced into the mucosa, either orally or intranasally, it stimulates T-regs instead. For trials of AD and other disorders, the ...